Optimizing the management of community-acquired respiratory tract infections in the age of antimicrobial resistance

Expert Review of Anti-Infective Therapy

Volumn 4, Issue 5, 2006, Pages 821-835

  Doern, Gary V ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

lactams; Antimicrobial resistance; Fluoroquinolones; Haemophilus influenzae; Macrolides; Moraxella catarrhalis; Streptococcus pneumoniae; Tetracyclines

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIBIOTIC AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CEFIXIME; CEFOTAXIME; CEFPODOXIME; CEFPROZIL; CEFTRIAXONE; CEFUROXIME; CLARITHROMYCIN; CLINDAMYCIN; COTRIMOXAZOLE; ERYTHROMYCIN; FOLIC ACID ANTAGONIST; KETOLIDE; LEVOFLOXACIN; LINCOSAMIDE DERIVATIVE; MACROLIDE; METRONIDAZOLE; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; STREPTOGRAMIN DERIVATIVE; SULFAMETHOXAZOLE; TELITHROMYCIN; TETRACYCLINE; TRIMETHOPRIM; UNINDEXED DRU G;

ANTIBIOTIC RESISTANCE; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; CONSENSUS; DIAGNOSTIC ACCURACY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; DRUG HALF LIFE; DRUG MEGADOSE; DRUG TREATMENT FAILURE; HEALTH EDUCATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LABORATORY TEST; LOW DRUG DOSE; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; NONHUMAN; PROGNOSIS; RESPIRATORY TRACT INFECTION; REVIEW; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; VACCINATION;

ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; COMMUNITY-ACQUIRED INFECTIONS; DISEASE MANAGEMENT; DRUG RESISTANCE, MICROBIAL; HUMANS; RESPIRATORY TRACT INFECTIONS;

EID: 33845440462     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.4.5.821     Document Type: Review

References (113)

1. McCaig LF, Hughes JM. Trends in antimicrobial drug prescribing among office-based physicians in the United States. JAMA 273(3), 214-219 (1995).
2. Sinus and Allergy Health Partnership. Antimicrobial treatment guidelines for acute bacterial rhinosinusitis. Otolaryngol. Head Neck Surg. 123 (1 Pt 2), 5-31 (2000).
3. Sethi S. Infectious exacerbations of chronic bronchitis: diagnosis and management. J. Antimicrob. Chemother 43(Suppl. A), 97-105 (1999).
4. Sokol W. Epidemiology of sinusitis in the primary care setting: results from the 1999-2000 respiratory surveillance program. Am. J. Med. 111 (Suppl. 9A), S19-S24 (2001)
5. Chan J, Hadley J. The microbiology of chronic rhinosinusitis: results of a community surveillance study. Ear Nose Throat J. 80(3), 143-145 (2001).
6. Leibovitz E, Jacobs MR, Dagan R. Haemophilus influenzae: a significant pathogen in acute otitis media. Pediatr. Infect. Dis. J. 23(12), 1142-1152 (2004).
7. Advisory Committee on Immunization Practices (ACIP). Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbidity Mortality Weekly Rep. 46, 1- 24 (2006).
8. Thornsberry C, Brown SD, Yee C, Bouchillon SK, Marler JK, Rich T. Increasing penicillin resistance in Streptococcus pneumoniae in the US. Infect. Med. 93(Suppl.), 15-24 (1993).
9. Doern GV, Brown SD. Antimicrobial susceptibility among community-acquired respiratory tract pathogens in the USA: data from PROTEKT US 2000-2001. J. Infect. 48(1), 56-65 (2004).
10. Doern, GV, Richter SS, Miller A et al. Antimicrobial resistance among Streptococcus pneumoniae in the United States: have we begun to turn the corner on resistance to certain antimicrobial classes? Clin. Infect. 41(2), 139-148 (2005).
11. Canton R. Resistance trends in Moraxella catarrhalis (PROTEKT years 1-3 [1999-2002]). J. Chemother. (Suppl. 6), 63-70 (2004).
12. Heilmann KP, Rice CL, Miller AL et al. Decreasing prevalence of β-lactamase production among respiratory tract isolates of haemophilus influenzae in the United States. Antimicrob. Agents Chemother. 6, 2561-2564 (2005).
13. Thornsberry C, Sahm DF, Kelly LJ et al. Regional trends in antimicrobial resistance among clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States: results from the TRUST Surveillance Program, 1999-2000. Clin. Infect. Dis. 34(Suppl. 1), S4-S16 (2002).
14. Hakenbeck R, Tarpay M, Tomasz A. Multiple changes of penicillin-binding proteins in pennicillin-resistant clinical isolates of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 17(3), 364-371 (1980).
15. File TM, Garau J. Jacobs MR, Wynne B, Twynholm M, Berkowitz E. Efficacy of a new pharmacokinetically enhanced formulation of amoxicillin/ clavulanate (2000/125 mg) in adults with community-acquired pneumonia caused by Streotococcus pneumoniae, including penicillin-resistant strains. Int. J. Antimicrob. Agents 25(2), 110-119 (2005).
16. File TM Jr, Jacobs MR, Poole MD, Wynne B. Outcome of treatment of respiratory tract infections due to Streptococcus pneumoniae, including drug-resistant strains, with pharmacokinetically enhanced amoxycillin/ clavulanate. Int. J. Antimicrob. Agents 20(4), 235-2347 (2002).
17. Medeiros AA, O'Brien TF. Ampicillin-resistant Haemophilus influenzae type B possessing a TEM-type β-lactamase but little permeability barrier to ampicillin. Lancet 1(7909), 716-719 (1975).
18. Bell SM, Hardy MJ, Pham JN, Jimenez AS, Gatus BJ. Resistance of haemophilus influenzae type b to ampicillin mediated by ROB-1 β-lactamase. Med. J Aust. 159(11-12), 834 (1993).
19. Rubin LG, Medeiros AA, Yolken RH, Moxon ER. Ampicillin treatment failure of apparently β-lactamase-negative Haemophilus influenzae type b meningitis due to novel beta-lactamase. Lancet 2(8254), 1008-1010 (1981).
20. Wallace RJ Jr, Steingrube VA, Nash DR et al. BRO β-lactamases of Branhamella catarrhalis and Moraxella subgenus Moraxella, including evidence for chromosomal beta-lactamase transfer by conjugation in B. catarrhalis, M. nonliquefaciens, and M. lacunata. Antimicrob Agents Chemother. 33(11), 1845-1854 (1989).
21. Alaedini A, Day RA. Identification of two penicillin-binding multienzyme complexes in Haemophilus influenzae. Biochem. Biophys. Res. Commun. 264(1), 191-195 (1999).
22. Vasquez D, Monro RF. Effects of some inhibitors of protein synthesis on the binding of aminoacyl tRNA to ribosomal subunits. Biochim. Biophys. Acta 142(1), 155-173 (1967).
23. Sutcliffe J, Tait-Kamradt A, Wondrack L. Streptococcus pneumoniae and Streptococcus pyogenes resistant to macrolides but sensitive to clindamycin: a common resistance pattern mediated by an efflux system. Antimicrob. Agents Chemother. 40(8), 1817-1824 (1996).
24. Tait-Kamradt A, Clancy J, Cronan M et al. mefE is necessary for the erythromycin-resistant M phenotype in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 41(10), 2251-2255 (1997).
25. Shortridge VD, Flamm RK, Ramer N, Beyer J, Tanaka SK. Novel mechanism of macrolide resistance in Streptococcus pneumoniae. Diagn. Microbiol. Infect. Dis. 26(2), 73-78 (1996).
26. Doern G, Brueggemann A, Huynh H, Wingert E. Antimicrobial resistance with Sreptococcus pneumoniae in the United States, 1997-98. Emerg. Infect. Dis. 5(6), 757-765 (1999).
27. Jenkins SG, Farrell DJ, Patel M, Lavin BS. Trends in anti-bacterial resistance among Streptococcus pneumoniae isolated in the USA, 2000-2003: PROTEKT US years 1-3. J. Infect. 51(5), 355-363 (2005).
28. Tait-Kamradt A, Davies T, Appelbaum PC et al. Two new mechanisms of macrolide resistance in clinical strains of Streptococcus pneumoniae from Eastern Europe and North America. Antimicrob. Agents Chemother 44(12), 3395-3401 (2000).
29. Fernandez-Munoz R, Monro RE, Torres-Pinedo R, Vazquez D. Substrate- and antibiotic-binding sites at the peptidyl-transferase centre of Escherichia coli ribosomes. Studies on the chloramphenicol. lincomycin and erythromycin sites. Eur. J. Biochem. 23(1), 185-193 (1971).
30. Shortridge VD, Doern GV, Brueggemann AB, Beyer JM, Flamm RK. Prevalence of macrolide resistance mechanisms in Streptococcus pneumoniae isolates from a multicenter antibiotic resistance surveillance study conducted in the United States in 1994-1995. Clin. Infect. Dis. 29(5), 1186-1188 (1999).
31. Balfour JA, Figgitt DP. Telithromycin. Drugs 61(6), 815-829 (2001).
32. Khodursky AB, Zechiedrich EL, Cozzarelli NR. Topoisomerase IV is a target of quinolones in Escherichia coli. Proc. Natl Acad. Sci. USA. 92(25), 11861-11805 (1995).
33. Pan XS, Fisher LM. DNA gyrase and topoisomerase IV are dual targets of clinafloxacin action in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 11, 2810-2816 (1998).
34. Tankovic J, Perichon B, Duval J, Courvalin P. Contribution of mutations in gyrA and parC genes to fluoroquinolone resistance of mutants of Streptococcus pneumoniae obtained in vivo and in vitro. Antimicrob. Agents Chemother. 40(11), 2505-2510 (1996).
35. Davies TA, Kelly LM, Hoellman DB et al. Activities and postantibiotic effects of gemifloxacin compared to those of 11 other agents against Haemophilus influenzae and Moraxalla catarrhalis. Antimicrob. Agents Chemother. 44(3), 633-639 (2000).
36. Davies TA, Kelly LM, Pankuch GA, Credito KL, Jacobs MR, Appelbaum PC. Antipneumococcal activities of gemifloxacin compared to those of nine other agents. Antimicrob. Agents Chemother. 44(2), 304-310 (2000).
37. Kaatz GW, Seo SM, Ruble CA. Efflux-mediated fluoroquinolone resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 37(5), 1086-1094 (1993).
38. Gill MJ, Brenwald NP, Wise R. Identification of an efflux pump gene, pmrA, associated with fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 43(1), 187-189 (1999).
39. Pikis A, Donkersloot JA, Rodriguez WJ, Keith JM. A conservative amino acid mutation in the chromosome-encoded dihydrofolate reductase confers trimethoprim resistance in Streptococcus pneumoniae. J. Infect. Dis. 178(3), 700-706 (1998).
40. Maskell JP, Sefton AM, Hall LM. Mechanism of sulfonamide resistance in clinical isolates of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 41(10), 2121-2126 (1997).
41. Brown SD, Farrell DJ, Morrissey I. Prevalence and molecular analysis of macrolide and fluoroquinolone resistance among isolates of Streptococcus pneumoniae collected during the 2000-2001 PROTEKT US Study. J. Clin. Microbiol. 42(11), 4980-49807 (2004).
42. Karlowsky JA, Jones ME, Thornsberry C, Evangelista AT, Yee YC, Sahm DF. Stable antimicrobial susceptibility rates for clinical isolates of Pseudomonas aeruginosa from the 2001-2003 tracking resistance in the United States today surveillance studies. Clin. Infect. Dis. 40(Suppl. 2), S89-S98 (2005).
43. Pottumarthy S, Fritsche TR, Sader HS, Stilwell MG, Jones RN. Susceptibility patterns of Streptococcus pneumoniae isolates in North America (2002-2003): contemporary in vitro activities of amoxicillin/ clavulanate and 15 other antimicrobial agents. Int. J. Antimicrob. Agents 25(4), 282-289 (2005).
44. Brueggemann AB, Coffman SL, Rhomberg P et al. Fluoroquinolone resistance in Streptococcus pneumoniae in United States since 1994-1995. Antimicrob. Agents Chemother. 46(3), 680-688 (2002).
45. Richter SS, Heilmann KP, Beekmann SE, Miller NJ, Rice CL, Doern GV. The molecular epidemiology of Streptococcus pneumoniae with quinolone resistance mutations. Clin. Infect. Dis. 40(2), 225-235 (2005).
46. Johnson DM, Sader HS, Fritsche TR, Biedenbach DJ, Jones RN. Susceptibility trends of Haemophilus influenzae and Moraxella catarrhalis against orally administered antimicrobial agents: five-year report from the SENTRY Antimicrobial Surveillance Program. Diagn. Microbiol. Infect. Dis. 47(1), 373-376 (2003).
47. Gordon KA, Biedenbach DJ, Jones RN. Comparison of Streptococcus pneumoniae and Haemophilus influenzae susceptibilities from community-acquired respiratory tract infections and hospitalized patients with pneumonia: five-year results for the SENTRY Antimicrobial Surveillance Program. Diagn. Microbiol. Infect. 46(4), 285-289 (2003).
48. Richter SS, Brueggemann AB, Huynh HK et al. A 1997-1998 national surveillance study: Moraxella catarrhalis and Haemophilus influenzae antimicrobial resistance in 34 US institutions. Int. J. Antimicrob. Agents 13(2), 99-107 (1999).
49. Doern GV, Brueggemann AB, Pierce G, Hogan T, Holley HP Jr, Rauch A. Prevalence of antimicrobial resistance among 723 outpatient clinical isolates of Moraxella catarrhalis in the United States in 1994 and 1995: results of a 30-center national surveillance study. Antimicrob. Agents Chemother. 40(12), 2884-2886 (1996).
50. Gomez-Barreto D, Calderon-Jaimes E, Rodriguez RS, los Monteros LE. Clinical outcome of invasive infections in children caused by highly penicillin-resistant Streptococcus pneumoniae compared with infections caused by penicillin-susceptible strains. Arch. Med. Res. 31(6), 592-598 (2000).
51. Falco V, Almirante B, Jordano Q et al. Influence of penicillin resistance on outcome in adult patients with invasive pneumococcal pneumonia: is penicillin useful against intermediately resistant strains? J. Antimicrob. Chemother. 54(2), 481-488 (2004).
52. Bonnard P, Lescure FX, Douadi Y et al. Community-acquired bacteraemic pneumococcal pneumonia in adults: effect of diminished penicillin susceptibility on clinical outcome. J. Infect. 51(1), 69-76 (2005).
53. Maugein J, Guillemot D, Dupont MJ et al. Clinical and microbiological epidemiology of Streptococcus pneumoniae bacteremia in eight French counties. Clin. Microbiol. Infect. 9(4), 280-288 (2003).
54. Ho PL, Que TL, Ng TK, Chiu SS, Yung RW, Tsang KW. Clinical outcomes of bacteremic pneumococcal infections in an area with high resistance. Eur. J. Clin. Microbiol. Infect. Dis. (2006).
55. Yu VL, Chiou CC, Feldman C et al. An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome. Clin. Infect. Dis. 37(2), 230-237 (2003).
56. Moroney JF, Fiore AE, Harrison LH et al. Clinical outcomes of bacteremic pneumococcal pneumonia in the era of antibiotic resistance. Clin. Infect. Dis. 33(6), 797-805 (2001).
57. Pallares R, Linares J, Vadillo M et al. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N. Engl. J. Med. 333(8), 474-480 (1995).
58. Pallares R, Gudiol F, Linares J et al. Risk factors and response to antibiotic therapy in adults with bacteremic pneumonia caused by penicillin-resistant pneumococci. N. Engl. J. Med. 317(1), 18-22 (1987).
59. Pallares R, Capdevila O, Linares J et al. The effect of cephalosporin resistance on mortality in adult patients with nonmeningeal systemic pneumococcal infections. Am. J. Med. 113(2), 120-126 (2002).
60. Ewig S, Ruiz M, Torres A et al. Pneumonia acquired in the community through drug-resistant Streptococcus pneumoniae. Am. J. Respir. Crit. Care. Med. 159(6), 1835-1842 (1999).
61. Lonks JR, Garau J, Gomez L et al. Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae. Clin. Infect. Dis. 35(5), 556-564 (2002).
62. Van Kerkhoven D, Peetermans WE, Verbist L, Verhaegen J. Breakthrough pneumococcal bacteraemia in patients treated with clarithromycin or oral β-lactams. J. Antimicrob. Chemother. 51(3), 691-696 (2003).
63. Daneman N, McGeer A, Green K, Low DE. Macrolide resistance in bacteremic pneumococcal disease: implications for patient management. Clin. Infect. 43(4), 432-438 (2006).
64. Pullman J, Boucner J, Patel M, Lavin B. Clinical and bacteriologic efficacy of telithromycin versus clarithromycin in patients with community-acquired pneumonia due Streptococcus pneumoniae including erythromycin-resistant strains. In: Proceedings of the Program and Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, CA, USA (2002) (Abstract L-372).
65. Bishai WR. Macrolide immunomodulatory effects and symptom resolution in acute exacerbation of chronic bronchitis and acute maxillary sinusitis: a focus on clarithromycin. Expert Rev. Anti. Infect. Ther. 4(3), 405-416 (2006).
66. Easmon CS, Ison CA, Kaye CM, Timewell RM, Dawson SG. Pharmacokinetics of metronidazole and its principal metabolites and their activity against Gardnerella vaginalis. Br. J. Vener. Dis. 58(4), 246-249 (1982).
67. Hoover WW, Barrett MS, Jones RN. Clarithromycin in vitro activity enhanced by its major metabolite, 14-hydroxyclarithromycin. Diagn. Microbiol. Infect. Dis. 15(3), 259-66 (1992).
68. Neu HC. Antibacterial activity of desacetylcefotaxime alone and in combination with cefotaxime. Rev. Infect. Dis. 4(Suppl.), S374-S378 (1982).
69. Chu SY, Deaton R, Cavanaugh J. Absolute bioavailability of clarithromycin after oral administration in humans. Antimicrob. Agents Chemother. 36(5), 1147-1150 (1992).
70. Anzueto A, Norris S. Clarithromycin in 2003: sustained efficacy and safety in an era of rising antibiotic resistance. Int. J. Antimicrob. Agents 24(1), 1-17 (2004).
71. Austrian R, Gold J. Pneumococcal bacteremia with especial reference to bacteremic pneumococcal pneumonia. Ann. Intern. Med. 60, 759-776 (1965).
72. Feikin DR, Schuchat A, Kolczak M et al. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997. Am. J. Public Health 90(2), 223-229 (2000).
73. Bishai WR. Clinical significance of pneumococcal resistance and factors influencing outcomes. Treat Respir. Med. 4(Suppl. 1), 19-23 (2005).
74. Ball P, Baquero F, Cars O et al. Antibiotic therapy of community respiratory tract infections: strategies for optimal outcomes and minimized resistance emergence. J. Antimicrob. Chemother. 49(1), 31-40 (2002).
75. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. 26(1), 1-10 (1998).
76. Gonzales R, Malone DC, Maselli JH, Sande MA. Excessive antibiotic use for acute respiratory infections in the United States. Clin. Infect. Dis. 33, 757-762 (2001).
77. Zhanel GG. Antibacterial drivers of resistance. Treat Repir. Med. 4(Suppl. 1), 13-8 (2005).
78. Guillemot D, Carbon C, Balkau B et al. Low dosage and long treatment duration of β-lactam: risk factors for carriage of penicillin-resistant Streptococcus pneumoniae. JAMA 279(5), 365-370 (1998).
79. Schrag SJ, Pena C, Fernandez J et al. Effect of short-course, high-dose amoxicillin therapy on resistant pneumococcal carriage: a randomized trial. JAMA 286(1), 49-56 (2001).
80. Conte JE Jr, Golden JA, Duncan S, McKenna E, Zurlinden E. Intrapulmonary pharmacokinetics of clarithromycin and of erythromycin. Antimicrob. Agents Chemother. 39(2), 334-348 (1995).
81. Conte JE Jr, Golden J, Duncan S, McKenna E, Lin E, Zurlinden E. Single-dose intrapulmonary pharmacokinetics of azithromycin, clarithromycin, ciprofloxacin, and cefuroxime in volunteer subjects. Antimicrob. Agents Chemother. 40(7), 1617-1622 (1996).
82. Patel KB, Xuan D, Tessier PR, Russomanno JH, Quintiliani R, Nightingale CH. Comparison of bronchopulmonary pharmacokinetics of clarithromycin and azithromycin. Antimicrob. Agents Chemother. 40(10), 2375-2379 (1996).
83. Rodvold KA, Gotfried MH, Danziger LH, Servi RJ. Intrapulmonary steady-state concentrations of clarithromycin and azithromycin in healthy adult volunteers. Antimicrob. Agents Chemother. 41(6), 1399-1402 (1997).
84. Beekmann SE, Diekema DJ, Heilmann KP, Richter SS, Doern GV. Macrolide use identified as risk factor for macrolide-resistant Streptococcus pneumoniae in a 17-center case-control study. Eur. J. Clin. Microbiol. Infect. Dis. 25(5), 335-339 (2006).
85. Ghaffar F, Muniz LS, Katz K et al. Effects of amoxicillin/clavulanate or azithromycin on nasopharyngeal carriage of Streptococcus pneumoniae and Haemophilus influenzae in children with acute otitis media. Clin. Infect. Dis. 31(4), 875-880 (2000).
86. Gray GC, Witucki PJ, Could MT et al. Randomized, placebo-controlled clinical trial of oral azithromycin prophylaxis against respiratory infections in a high-risk, young adult population. Clin. Infect. Dis. 33(7), 983-989 (2001).
87. Leach AJ, Shelby-James TM, Mayo M et al. A prospective study of the impact of community-based azithromycin treatment of trachoma on carriage and resistance of Streptococcus pneumoniae. Clin. Infect. Dis. 24(3), 356-362 (1997).
88. Vanderkooi OG, Low DE, Green K, Powis JE, McGeer A. Predicting antimicrobial resistance in invasive pneumococcal infections. Clin. Infect. Dis. 40(9), 1288-1297 (2005).
89. Blondeau JM, Hansen G, Metzler K, Hedlin P. The role of PK/PD parameters to avoid selection and increase of resistance: mutant prevention concentration. J. Chemother. 16(Suppl. 3), 1-19 (2004).
90. Sierra JM, Cabeza JG, Ruiz CM et al. The selection of resistance to and the mutagenicity of different fluoroquinolones in Staphylococcus aureus and Streptococcus pneumoniae. Clin. Microbiol. Infect. 11(9), 750-758 (2005).
91. Zhanel GG, Walters M, Laing N, Hoban DJ. In vitro pharmacodynamic modelling simulating free serum concentrations of fluoroquinolones against multidrug-resistant Streptococcus pneumoniae. J. Antimicrob. Chemother. 47(4), 435-440 (2001).
92. Croisier D, Etienne M, Bergoin E et al. Mutant selection window in levofloxacin and moxifloxacin treatments of experimental pneumococcal pneumonia in a rabbit model of human therapy. Antimicrob. Agents Chemother. 48(5), 1699-1707 (2004).
93. Richter SS, Heilmann KP, Coffman SL et al. The molecular epidemiology of penicillin-resistant Streptococcus pneumoniae in the United States, 1994-2000. Clin. Infect. Dis. 34(3), 330-339 (2002).
94. Gherardi G, Whitney CG, Facklam RR, Beall B. Major related sets of antibiotic-resistant pneumococci in the United States as determined by pulsed-field gel electrophoresis and pbp1a-pbp2b-pbp2x-dhf restriction profiles. J. Infect. Dis. 181(1), 216-229 (2000).
95. Corso A, Severina EP, Petruk VF, Mauriz YR, Tomasz A. Molecular characterization of penicillin-resistant Streptococcus pneumoniae isolates causing respiratory disease in the United States. Microb. Drug Resist. 4(4), 325-337 (1998).
96. Schrag SJ, Beall B, Dowell SF. Limiting the spread of resistant pneumococci: biological and epidemiologic evidence for the effectiveness of alternative interventions. Clin. Microbiol. Rev. 13(4), 588-601 (2000).
97. Kyaw MH, Lynfield R, Schaffner W et al. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N. Engl. J. Med. 354(14), 1455-1463 (2006).
98. Black SB, Shinefield HR, Hansen J, Elvin L, Laufer D, Malinoski F. Postlicensure evaluation of the effectiveness of seven valent pneumococcal conjugate vaccine. Pediatr. Infect. Dis. J. 20(12), 1105-1107 (2001).
99. Huang SS, Platt R, Rifas-Shiman SL, Pelton SI, Goldmann D, Finkelstein JA. Post-PCV7 changes in colonizing pneumococcal serotypes in 16 Massachusetts communities, 2001 and 2004. Pediatrics 116(3), e408-e413 (2005).
100. Talbot TR, Poehling KA, Hartert TV et al. Reduction in high rates of antibiotic-nonsusceptible invasive pneumococcal disease in Tennessee after introduction of the pneumococcal conjugate vaccine. Clin. Infect. Dis. 39(5), 641-648 (2004).
101. Whitney CG, Farley MM, Hadler J et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N. Engl. J. Med. 348(18), 1737-1746 (2003).
102. Block SL, Hedrick J, Harrison CJ et al. Community-wide vaccination with the heptavalent pneumococcal conjugate significantly alters the microbiology of acute otitis media. Pediatr. Infect. Dis. J. 23(9), 829-833 (2004).
103. Casey JR, Pichichero ME. Changes in frequency and pathogens causing acute otitis media in 1995-2003. Pediatr. Infect. Dis. J. 23(9), 824-828 (2004).
104. Caspary H, Welch JC, Lawson L et al. Impact of pneumococcal polysaccharide vaccine (Prevnar) on middle ear fluid in children undergoing tympanostomy tube insertion. Laryngoscope 114(6), 975-980 (2004).
105. Pai R, Moore MR, Pilishvili T, Gertz RE, Whitney CG, Beall B. Postvaccine genetic structure of Streptococcus pneumoniae serotype 19A from children in the United States. J. Infect. Dis. 192(11), 1988-1995 (2005).
106. Jorgensen JH, Doern GV, Maher LA, Howell AW, Redding JS. Antimicrobial resistance among respiratory isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae in the United States. Antimicrob. Agents Chemother. 34(11), 2075-2080 (1990).
107. Barry AL, Pfaller MA, Fuchs PC, Packer RR. In vitro activities of 12 orally administered antimicrobial agents against four species of bacterial respiratory pathogens from U.S. Medical Centers in 1992 and 1993. Antimicrob. Agents Chemother. 38(10), 2419-2425 (1994).
108. Doern GV, Brueggemann A, Holley HP Jr, Rauch AM. Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: results of a 30-center national surveillance study. Antimicrob. Agents Chemother. 40(5), 1208-1213 (1996).
109. Doern GV, Jones RN, Pfaller MA, Kugler K. Haemophilus influenzae and Moraxella catarrhalis from patients with community-acquired respiratory tract infections: antimicrobial susceptibility patterns from the SENTRY antimicrobial Surveillance Program (United States and Canada, 1997). Antimicrob. Agents Chemother. 43(2), 385-389 (1999).
110. Sahm DF, Karlowsky JA, Kelly LJ et al. Need for annual surveillance of antimicrobial resistance in Streptococcus pneumoniae in the United States: 2-year longitudinal analysis. Antimicrob. Agents Chemother. 45(4), 1037-1042 (2001).
111. Doern GV, Heilmann KP, Huynh HK, Rhomberg PR, Coffman SL, Brueggemann AB. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000, including a comparison of resistance rates since 1994-1995. Antimicrob. Agents Chemother. 45(6), 1721-1729 (2001).
112. Karlowsky JA, Thornsberry C, Jones ME, Evangelista AT, Critchley IA, Sahm DF. Factors associated with relative rates of antimicrobial resistance among Streptococcus pneumoniae in the United States: results from the TRUST Surveillance Program (1998-2002). Clin. Infect. Dis. 36(8), 963-970 (2003).
113. Karlowsky JA, Thornsberry C, Critchley IA et al. Susceptibilities to levofloxacin in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis clinical isolates from children: results from 2000-2001 and 2001-2002 TRUST studies in the United States. Antimicrob. Agents Chemother. 47(6), 1790-1797 (2003).